ARTICLE | Finance
Ansun’s China ambitions
How Chinese series A syndicate could help Ansun crack China’s antiviral market
May 18, 2018 8:06 PM UTC
The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market.
Sinopharm Healthcare Fund and Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures and Joincap Investment. Ansun interim CEO Nancy Chang said undisclosed U.S.-based investors also participated. ...